By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
.
Embolic protection devices have the potential to reduce unfavourable clinical outcomes by preventing or reducing plaque material from reaching the distal bed. They are frequently utilised in carotid artery stenting procedures and saphenous vein graft (SVG) surgeries. A thin, porous polymeric membrane supported by a tiny metal framework makes up the filter.
The filter is inflated and a standard angioplasty is carried out after passing through the lesion and arriving at the distal location. Embodiments are caught in the filter as the blood flows through it. By collapsing the filter at the end of the treatment, embolic debris are trapped and can only be removed by retracting the wire into a retrieving catheter.
The Global Embolic Filter system market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
The FilterWire EZTM Embolic Protection System was launched by Boston Scientific. It is intended to contain and remove embolic material that might become dislodged during an interventional saphenous vein graft (SVG) procedure; in the absence of such measures, embolic material may enter the microvasculature and raise the risk of a heart attack.
A sizable patient group was unmet due to the lack of a filter-based solution for SVGs smaller than 3.0 mm. Boston Scientific’s introduction of this smaller size enables doctors to provide this standard of care in a wider variety of SVG vessels.
A low-profile embolic protection device called the FilterWire EZ System has been successfully demonstrated to catch and remove embolic debris, reducing problems during balloon angioplasty and stenting treatments in SVGs (2).
Patients who have undergone coronary artery bypass graft (CABG) surgery, in which a vascular taken from the patient’s leg is surgically connected to the arteries of the heart, are at risk of developing SVG disease.
Bypassing the obstructed artery, blood is routed through the surgically implanted SVG, boosting heart blood flow. SVG disease differs from native coronary artery disease in its complexity and rate of progression, which can make treating it more difficult for doctors and put patients at risk.
